What is Avid Bioservices, Inc. (CDMO)?

Avid Bioservices, Inc. (CDMO) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of CDMO?

The current price of CDMO is $12.49. Prices are updated in real time on Stocks360.

What is CDMO's price-to-earnings (PE) ratio?

CDMO's trailing twelve-month PE ratio is -5.60, based on current price and earnings per share data available on Stocks360.

What is CDMO's market capitalization?

CDMO's market capitalization is $798,901,617.00, placing it in the small-cap tier.

Avid Bioservices, Inc. (CDMO)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$12.49

Market Cap

$798.90M

PE (TTM)

-5.60

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.41

Day Range

$12.49 – $12.49

52-wk Range

$5.90 – $12.51

Avg Volume

N/A

Volume

0.00

Avid Bioservices, Inc. (CDMO) is a publicly traded company in the Healthcare sector. Latest price: $12.49. Market cap $798.90M. Trailing PE -5.60. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Earnings

Most Recent

Dec 10, 2024

EPS $-0.27 vs est. $-0.12

Missed by $0.15

Proprietary Signals

Signal snapshot temporarily unavailable.

About Avid Bioservices, Inc.

Avid Bioservices, Inc. operates as a Contract Development and Manufacturing Organization (CDMO), specializing in the development and CGMP-compliant production of biopharmaceutical drug substances. Their core expertise lies in compounds derived from mammalian cell culture, providing both clinical and commercial scale manufacturing solutions. The company is proficient in producing critical therapeutics such as monoclonal antibodies and recombinant proteins. Beyond manufacturing, their comprehensive service portfolio encompasses CGMP manufacturing for drug substances, bulk packaging, rigorous release and stability testing, and essential regulatory submission and support. Additionally, Avid Bioservices offers a range of process development services, including the optimization of upstream and downstream processes, alongside the development, testing, and characterization of analytical methods. Avid Bioservices primarily serves clients within the biotechnology and biopharmaceutical industries. The company, which was originally incorporated in 1981, was known as Peregrine Pharmaceuticals, Inc. before officially rebranding to Avid Bioservices, Inc. in January 2018. Its corporate headquarte…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-5.60×
P/S (TTM)	5.71×
P/B	12.96×
PEG	0.02×
P/FCF (TTM)	-38.31×
EV / EBITDA	-84.37×
EV / Sales	6.92×
Earnings Yield	-17.83%
Free Cash Flow Yield	-2.61%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$968.63M
Revenue (TTM)	$139.91M
Net Income (TTM)	-$142.46M
Free Cash Flow (TTM)	$1.82M
Net Debt	$169.73M
Working Capital	$33.44M
Gross Margin	5.23%
Operating Margin	-13.35%
Net Margin	-100.60%
Return on Equity	-112.44%
Return on Invested Capital	-6.95%